Type |
Details |
Score |
Gene |
Type: |
gene |
Organism: |
human |
|
•
•
•
•
•
|
Gene |
Type: |
gene |
Organism: |
frog, western clawed |
|
•
•
•
•
•
|
Gene |
|
•
•
•
•
•
|
Gene |
Type: |
gene |
Organism: |
chimpanzee |
|
•
•
•
•
•
|
Gene |
Type: |
gene |
Organism: |
dog, domestic |
|
•
•
•
•
•
|
Gene |
Type: |
gene |
Organism: |
cattle |
|
•
•
•
•
•
|
Gene |
Type: |
gene |
Organism: |
chicken |
|
•
•
•
•
•
|
Gene |
Type: |
gene |
Organism: |
macaque, rhesus |
|
•
•
•
•
•
|
Protein Coding Gene |
Type: |
protein_coding_gene |
Organism: |
mouse, laboratory |
|
•
•
•
•
•
|
Publication |
First Author: |
Kommaddi RP |
Year: |
2011 |
Journal: |
FASEB J |
Title: |
Trk-dependent ADAM17 activation facilitates neurotrophin survival signaling. |
Volume: |
25 |
Issue: |
6 |
Pages: |
2061-70 |
|
•
•
•
•
•
|
Publication |
First Author: |
Wang Y |
Year: |
2013 |
Journal: |
Biochim Biophys Acta |
Title: |
ADAM17 cleaves CD16b (FcγRIIIb) in human neutrophils. |
Volume: |
1833 |
Issue: |
3 |
Pages: |
680-5 |
|
•
•
•
•
•
|
Publication |
First Author: |
Arndt PG |
Year: |
2011 |
Journal: |
PLoS One |
Title: |
Leukocyte ADAM17 regulates acute pulmonary inflammation. |
Volume: |
6 |
Issue: |
5 |
Pages: |
e19938 |
|
•
•
•
•
•
|
Publication |
First Author: |
Pellegatta M |
Year: |
2022 |
Journal: |
J Neurosci |
Title: |
ADAM17 Regulates p75(NTR)-Mediated Fibrinolysis and Nerve Remyelination. |
Volume: |
42 |
Issue: |
12 |
Pages: |
2433-2447 |
|
•
•
•
•
•
|
Publication |
First Author: |
Shoykhet M |
Year: |
2023 |
Journal: |
Front Cell Dev Biol |
Title: |
Cardiomyocyte cohesion is increased after ADAM17 inhibition. |
Volume: |
11 |
|
Pages: |
1021595 |
|
•
•
•
•
•
|
Publication |
First Author: |
Saad MI |
Year: |
2021 |
Journal: |
Am J Respir Cell Mol Biol |
Title: |
ADAM17 Deficiency Protects against Pulmonary Emphysema. |
Volume: |
64 |
Issue: |
2 |
Pages: |
183-195 |
|
•
•
•
•
•
|
Publication |
First Author: |
Saad MI |
Year: |
2020 |
Journal: |
Carcinogenesis |
Title: |
The ADAM17 protease promotes tobacco smoke carcinogen-induced lung tumorigenesis. |
Volume: |
41 |
Issue: |
4 |
Pages: |
527-538 |
|
•
•
•
•
•
|
Publication |
First Author: |
Sel S |
Year: |
2012 |
Journal: |
Ann Anat |
Title: |
Expression analysis of ADAM17 during mouse eye development. |
Volume: |
194 |
Issue: |
4 |
Pages: |
334-8 |
|
•
•
•
•
•
|
Publication |
First Author: |
Sommer A |
Year: |
2016 |
Journal: |
Nat Commun |
Title: |
Phosphatidylserine exposure is required for ADAM17 sheddase function. |
Volume: |
7 |
|
Pages: |
11523 |
|
•
•
•
•
•
|
Publication |
First Author: |
Fredrickx E |
Year: |
2020 |
Journal: |
Glia |
Title: |
Ablation of neuronal ADAM17 impairs oligodendrocyte differentiation and myelination. |
Volume: |
68 |
Issue: |
6 |
Pages: |
1148-1164 |
|
•
•
•
•
•
|
Publication |
First Author: |
Caolo V |
Year: |
2015 |
Journal: |
Angiogenesis |
Title: |
ADAM10 and ADAM17 have opposite roles during sprouting angiogenesis. |
Volume: |
18 |
Issue: |
1 |
Pages: |
13-22 |
|
•
•
•
•
•
|
Publication |
First Author: |
Groot AJ |
Year: |
2013 |
Journal: |
J Invest Dermatol |
Title: |
Epidermal ADAM17 is dispensable for notch activation. |
Volume: |
133 |
Issue: |
9 |
Pages: |
2286-8 |
|
•
•
•
•
•
|
Publication |
First Author: |
Wang Y |
Year: |
2009 |
Journal: |
J Immunol |
Title: |
Regulation of mature ADAM17 by redox agents for L-selectin shedding. |
Volume: |
182 |
Issue: |
4 |
Pages: |
2449-57 |
|
•
•
•
•
•
|
Publication |
First Author: |
Bolik J |
Year: |
2022 |
Journal: |
J Exp Med |
Title: |
Inhibition of ADAM17 impairs endothelial cell necroptosis and blocks metastasis. |
Volume: |
219 |
Issue: |
1 |
|
|
•
•
•
•
•
|
Publication |
First Author: |
West MA |
Year: |
2008 |
Journal: |
J Cell Biol |
Title: |
TLR ligand-induced podosome disassembly in dendritic cells is ADAM17 dependent. |
Volume: |
182 |
Issue: |
5 |
Pages: |
993-1005 |
|
•
•
•
•
•
|
Publication |
First Author: |
Mukerjee S |
Year: |
2019 |
Journal: |
Hypertension |
Title: |
ACE2 and ADAM17 Interaction Regulates the Activity of Presympathetic Neurons. |
Volume: |
74 |
Issue: |
5 |
Pages: |
1181-1191 |
|
•
•
•
•
•
|
Publication |
First Author: |
Schmidt S |
Year: |
2018 |
Journal: |
J Exp Med |
Title: |
ADAM17 is required for EGF-R-induced intestinal tumors via IL-6 trans-signaling. |
Volume: |
215 |
Issue: |
4 |
Pages: |
1205-1225 |
|
•
•
•
•
•
|
Publication |
First Author: |
Becker AM |
Year: |
2015 |
Journal: |
Exp Hematol |
Title: |
ADAM17 limits the expression of CSF1R on murine hematopoietic progenitors. |
Volume: |
43 |
Issue: |
1 |
Pages: |
44-52.e1-3 |
|
•
•
•
•
•
|
Publication |
First Author: |
Kefaloyianni E |
Year: |
2016 |
Journal: |
JCI Insight |
Title: |
ADAM17 substrate release in proximal tubule drives kidney fibrosis. |
Volume: |
1 |
Issue: |
13 |
|
|
•
•
•
•
•
|
Publication |
First Author: |
Nicolaou A |
Year: |
2017 |
Journal: |
Arterioscler Thromb Vasc Biol |
Title: |
Adam17 Deficiency Promotes Atherosclerosis by Enhanced TNFR2 Signaling in Mice. |
Volume: |
37 |
Issue: |
2 |
Pages: |
247-257 |
|
•
•
•
•
•
|
Publication |
First Author: |
Hall KC |
Year: |
2013 |
Journal: |
Mol Cell Biol |
Title: |
ADAM17 controls endochondral ossification by regulating terminal differentiation of chondrocytes. |
Volume: |
33 |
Issue: |
16 |
Pages: |
3077-90 |
|
•
•
•
•
•
|
Publication |
First Author: |
Hassemer EL |
Year: |
2013 |
Journal: |
Invest Ophthalmol Vis Sci |
Title: |
ADAM17 transactivates EGFR signaling during embryonic eyelid closure. |
Volume: |
54 |
Issue: |
1 |
Pages: |
132-40 |
|
•
•
•
•
•
|
Publication |
First Author: |
Saad MI |
Year: |
2022 |
Journal: |
Proc Natl Acad Sci U S A |
Title: |
Blockade of the protease ADAM17 ameliorates experimental pancreatitis. |
Volume: |
119 |
Issue: |
42 |
Pages: |
e2213744119 |
|
•
•
•
•
•
|
GXD Expression |
Probe: |
MGI:6166928 |
Assay Type: |
RNA in situ |
Annotation Date: |
2018-07-25 |
Strength: |
Present |
Sex: |
Not Specified |
Emaps: |
EMAPS:1689419 |
Pattern: |
Not Specified |
Stage: |
TS19 |
Assay Id: |
MGI:6189733 |
Age: |
embryonic day 11.5 |
|
|
Specimen Label: |
Table S2 - E11.5 - Adam17 |
Detected: |
true |
Specimen Num: |
1 |
|
•
•
•
•
•
|
GXD Expression |
Probe: |
MGI:6166928 |
Assay Type: |
RNA in situ |
Annotation Date: |
2018-07-25 |
Strength: |
Present |
Sex: |
Not Specified |
Emaps: |
EMAPS:1689421 |
Pattern: |
Not Specified |
Stage: |
TS21 |
Assay Id: |
MGI:6189733 |
Age: |
embryonic day 13.5 |
|
|
Specimen Label: |
Table S2 - E13.5 - Adam17 |
Detected: |
true |
Specimen Num: |
2 |
|
•
•
•
•
•
|
GXD Expression |
Probe: |
MGI:6166928 |
Assay Type: |
RNA in situ |
Annotation Date: |
2018-07-25 |
Strength: |
Absent |
Sex: |
Male |
Emaps: |
EMAPS:1689426 |
|
Stage: |
TS26 |
Assay Id: |
MGI:6189733 |
Age: |
embryonic day 18.5 |
|
|
Specimen Label: |
Table S2 - E18.5 - Adam17 |
Detected: |
false |
Specimen Num: |
4 |
|
•
•
•
•
•
|
GXD Expression |
Probe: |
MGI:6166928 |
Assay Type: |
RNA in situ |
Annotation Date: |
2018-07-25 |
Strength: |
Absent |
Sex: |
Male |
Emaps: |
EMAPS:1689428 |
|
Stage: |
TS28 |
Assay Id: |
MGI:6189733 |
Age: |
postnatal day 4 |
|
|
Specimen Label: |
Table S2 - P4 - Adam17 |
Detected: |
false |
Specimen Num: |
5 |
|
•
•
•
•
•
|
GXD Expression |
Probe: |
MGI:6166928 |
Assay Type: |
RNA in situ |
Annotation Date: |
2018-07-25 |
Strength: |
Absent |
Sex: |
Male |
Emaps: |
EMAPS:1689428 |
|
Stage: |
TS28 |
Assay Id: |
MGI:6189733 |
Age: |
postnatal day 28 |
|
|
Specimen Label: |
Table S2 - P28 - Adam17 |
Detected: |
false |
Specimen Num: |
7 |
|
•
•
•
•
•
|
GXD Expression |
Probe: |
MGI:6166928 |
Assay Type: |
RNA in situ |
Annotation Date: |
2018-07-25 |
Strength: |
Present |
Sex: |
Male |
Emaps: |
EMAPS:1689424 |
Pattern: |
Not Specified |
Stage: |
TS24 |
Assay Id: |
MGI:6189733 |
Age: |
embryonic day 15.5 |
|
|
Specimen Label: |
Table S2 - E15.5 - Adam17 |
Detected: |
true |
Specimen Num: |
3 |
|
•
•
•
•
•
|
GXD Expression |
Probe: |
MGI:6166928 |
Assay Type: |
RNA in situ |
Annotation Date: |
2018-07-25 |
Strength: |
Absent |
Sex: |
Male |
Emaps: |
EMAPS:1689428 |
|
Stage: |
TS28 |
Assay Id: |
MGI:6189733 |
Age: |
postnatal day 14 |
|
|
Specimen Label: |
Table S2 - P14 - Adam17 |
Detected: |
false |
Specimen Num: |
6 |
|
•
•
•
•
•
|
Publication |
First Author: |
Kubo S |
Year: |
2022 |
Journal: |
Nat Immunol |
Title: |
Congenital iRHOM2 deficiency causes ADAM17 dysfunction and environmentally directed immunodysregulatory disease. |
Volume: |
23 |
Issue: |
1 |
Pages: |
75-85 |
|
•
•
•
•
•
|
Publication |
First Author: |
Marczynska J |
Year: |
2014 |
Journal: |
J Immunol |
Title: |
The role of metalloproteinase ADAM17 in regulating ICOS ligand-mediated humoral immune responses. |
Volume: |
193 |
Issue: |
6 |
Pages: |
2753-63 |
|
•
•
•
•
•
|
Publication |
First Author: |
Badenes M |
Year: |
2023 |
Journal: |
Life Sci Alliance |
Title: |
The ADAM17 sheddase complex regulator iTAP/Frmd8 modulates inflammation and tumor growth. |
Volume: |
6 |
Issue: |
4 |
|
|
•
•
•
•
•
|
Publication |
First Author: |
Li Y |
Year: |
2006 |
Journal: |
Blood |
Title: |
ADAM17 deficiency by mature neutrophils has differential effects on L-selectin shedding. |
Volume: |
108 |
Issue: |
7 |
Pages: |
2275-9 |
|
•
•
•
•
•
|
Publication |
First Author: |
Aktas B |
Year: |
2005 |
Journal: |
J Biol Chem |
Title: |
Aspirin induces platelet receptor shedding via ADAM17 (TACE). |
Volume: |
280 |
Issue: |
48 |
Pages: |
39716-22 |
|
•
•
•
•
•
|
Publication |
First Author: |
Long C |
Year: |
2012 |
Journal: |
J Leukoc Biol |
Title: |
ADAM17 activation in circulating neutrophils following bacterial challenge impairs their recruitment. |
Volume: |
92 |
Issue: |
3 |
Pages: |
667-72 |
|
•
•
•
•
•
|
Publication |
First Author: |
Bozkulak EC |
Year: |
2009 |
Journal: |
Mol Cell Biol |
Title: |
Selective use of ADAM10 and ADAM17 in activation of Notch1 signaling. |
Volume: |
29 |
Issue: |
21 |
Pages: |
5679-95 |
|
•
•
•
•
•
|
Publication |
First Author: |
Schumacher N |
Year: |
2022 |
Journal: |
Biochim Biophys Acta Mol Cell Res |
Title: |
ADAM17 orchestrates Interleukin-6, TNFα and EGF-R signaling in inflammation and cancer. |
Volume: |
1869 |
Issue: |
1 |
Pages: |
119141 |
|
•
•
•
•
•
|
Publication |
First Author: |
Suzuki S |
Year: |
2020 |
Journal: |
Am J Physiol Lung Cell Mol Physiol |
Title: |
ADAM17 protects against elastase-induced emphysema by suppressing CD62L+ leukocyte infiltration in mice. |
Volume: |
318 |
Issue: |
6 |
Pages: |
L1172-L1182 |
|
•
•
•
•
•
|
Publication |
First Author: |
Kawai T |
Year: |
2017 |
Journal: |
Hypertension |
Title: |
Vascular ADAM17 (a Disintegrin and Metalloproteinase Domain 17) Is Required for Angiotensin II/β-Aminopropionitrile-Induced Abdominal Aortic Aneurysm. |
Volume: |
70 |
Issue: |
5 |
Pages: |
959-963 |
|
•
•
•
•
•
|
Publication |
First Author: |
Chalaris A |
Year: |
2010 |
Journal: |
J Exp Med |
Title: |
Critical role of the disintegrin metalloprotease ADAM17 for intestinal inflammation and regeneration in mice. |
Volume: |
207 |
Issue: |
8 |
Pages: |
1617-24 |
|
•
•
•
•
•
|
Publication |
First Author: |
Cabron AS |
Year: |
2018 |
Journal: |
J Immunol |
Title: |
Structural and Functional Analyses of the Shedding Protease ADAM17 in HoxB8-Immortalized Macrophages and Dendritic-like Cells. |
Volume: |
201 |
Issue: |
10 |
Pages: |
3106-3118 |
|
•
•
•
•
•
|
Publication |
First Author: |
Li Y |
Year: |
2018 |
Journal: |
Exp Cell Res |
Title: |
ADAM17 promotes cell migration and invasion through the integrin β1 pathway in hepatocellular carcinoma. |
Volume: |
370 |
Issue: |
2 |
Pages: |
373-382 |
|
•
•
•
•
•
|
Publication |
First Author: |
Canault M |
Year: |
2010 |
Journal: |
PLoS One |
Title: |
The lack of ADAM17 activity during embryonic development causes hemorrhage and impairs vessel formation. |
Volume: |
5 |
Issue: |
10 |
Pages: |
e13433 |
|
•
•
•
•
•
|
Publication |
First Author: |
Schwarz J |
Year: |
2014 |
Journal: |
J Biol Chem |
Title: |
Polo-like kinase 2, a novel ADAM17 signaling component, regulates tumor necrosis factor α ectodomain shedding. |
Volume: |
289 |
Issue: |
5 |
Pages: |
3080-93 |
|
•
•
•
•
•
|
Publication |
First Author: |
Weskamp G |
Year: |
2010 |
Journal: |
Circ Res |
Title: |
Pathological neovascularization is reduced by inactivation of ADAM17 in endothelial cells but not in pericytes. |
Volume: |
106 |
Issue: |
5 |
Pages: |
932-40 |
|
•
•
•
•
•
|
Publication |
First Author: |
Gutsaeva DR |
Year: |
2020 |
Journal: |
Int J Mol Sci |
Title: |
Inactivation of Endothelial ADAM17 Reduces Retinal Ischemia-Reperfusion Induced Neuronal and Vascular Damage. |
Volume: |
21 |
Issue: |
15 |
|
|
•
•
•
•
•
|
Publication |
First Author: |
Zhang X |
Year: |
2021 |
Journal: |
Biochem Biophys Res Commun |
Title: |
ADAM10 and ADAM17 are degraded by lysosomal pathway via asparagine endopeptidase. |
Volume: |
537 |
|
Pages: |
15-21 |
|
•
•
•
•
•
|
Publication |
First Author: |
Long C |
Year: |
2010 |
Journal: |
J Leukoc Biol |
Title: |
In vivo role of leukocyte ADAM17 in the inflammatory and host responses during E. coli-mediated peritonitis. |
Volume: |
87 |
Issue: |
6 |
Pages: |
1097-101 |
|
•
•
•
•
•
|
Publication |
First Author: |
Tang B |
Year: |
2020 |
Journal: |
FASEB J |
Title: |
Substrate-selective protein ectodomain shedding by ADAM17 and iRhom2 depends on their juxtamembrane and transmembrane domains. |
Volume: |
34 |
Issue: |
4 |
Pages: |
4956-4969 |
|
•
•
•
•
•
|
Publication |
First Author: |
Lownik JC |
Year: |
2020 |
Journal: |
Biochem Biophys Res Commun |
Title: |
B cell ADAM17 controls T cell independent humoral immune responses through regulation of TACI and CD138. |
Volume: |
522 |
Issue: |
2 |
Pages: |
442-447 |
|
•
•
•
•
•
|
Publication |
First Author: |
Bell JH |
Year: |
2007 |
Journal: |
J Leukoc Biol |
Title: |
Role of ADAM17 in the ectodomain shedding of TNF-alpha and its receptors by neutrophils and macrophages. |
Volume: |
82 |
Issue: |
1 |
Pages: |
173-6 |
|
•
•
•
•
•
|
Publication |
First Author: |
Murthy A |
Year: |
2012 |
Journal: |
Immunity |
Title: |
Notch activation by the metalloproteinase ADAM17 regulates myeloproliferation and atopic barrier immunity by suppressing epithelial cytokine synthesis. |
Volume: |
36 |
Issue: |
1 |
Pages: |
105-19 |
|
•
•
•
•
•
|
Publication |
First Author: |
Vidal PM |
Year: |
2013 |
Journal: |
Cell Death Dis |
Title: |
ADAM17 is a survival factor for microglial cells in vitro and in vivo after spinal cord injury in mice. |
Volume: |
4 |
|
Pages: |
e954 |
|
•
•
•
•
•
|
Publication |
First Author: |
Holdt LM |
Year: |
2008 |
Journal: |
Arterioscler Thromb Vasc Biol |
Title: |
Increased ADAM17 mRNA expression and activity is associated with atherosclerosis resistance in LDL-receptor deficient mice. |
Volume: |
28 |
Issue: |
6 |
Pages: |
1097-103 |
|
•
•
•
•
•
|
Publication |
First Author: |
Wang Y |
Year: |
2010 |
Journal: |
J Immunol |
Title: |
ADAM17 activity and other mechanisms of soluble L-selectin production during death receptor-induced leukocyte apoptosis. |
Volume: |
184 |
Issue: |
8 |
Pages: |
4447-54 |
|
•
•
•
•
•
|
Publication |
First Author: |
Palau V |
Year: |
2021 |
Journal: |
Int J Mol Sci |
Title: |
Both Specific Endothelial and Proximal Tubular Adam17 Deletion Protect against Diabetic Nephropathy. |
Volume: |
22 |
Issue: |
11 |
|
|
•
•
•
•
•
|
Publication |
First Author: |
Rabie T |
Year: |
2005 |
Journal: |
J Biol Chem |
Title: |
Evidence for a role of ADAM17 (TACE) in the regulation of platelet glycoprotein V. |
Volume: |
280 |
Issue: |
15 |
Pages: |
14462-8 |
|
•
•
•
•
•
|
Publication |
First Author: |
Hall KC |
Year: |
2012 |
Journal: |
PLoS One |
Title: |
Interleukin-1 stimulates ADAM17 through a mechanism independent of its cytoplasmic domain or phosphorylation at threonine 735. |
Volume: |
7 |
Issue: |
2 |
Pages: |
e31600 |
|
•
•
•
•
•
|
Publication |
First Author: |
Saad MI |
Year: |
2019 |
Journal: |
EMBO Mol Med |
Title: |
ADAM17 selectively activates the IL-6 trans-signaling/ERK MAPK axis in KRAS-addicted lung cancer. |
Volume: |
11 |
Issue: |
4 |
|
|
•
•
•
•
•
|
Publication |
First Author: |
Ford BM |
Year: |
2013 |
Journal: |
Am J Physiol Renal Physiol |
Title: |
ADAM17 mediates Nox4 expression and NADPH oxidase activity in the kidney cortex of OVE26 mice. |
Volume: |
305 |
Issue: |
3 |
Pages: |
F323-32 |
|
•
•
•
•
•
|
Publication |
First Author: |
Zbodakova O |
Year: |
2021 |
Journal: |
Sci Rep |
Title: |
ADAM10 and ADAM17 regulate EGFR, c-Met and TNF RI signalling in liver regeneration and fibrosis. |
Volume: |
11 |
Issue: |
1 |
Pages: |
11414 |
|
•
•
•
•
•
|
Publication |
First Author: |
Pruessmeyer J |
Year: |
2014 |
Journal: |
Blood |
Title: |
Leukocytes require ADAM10 but not ADAM17 for their migration and inflammatory recruitment into the alveolar space. |
Volume: |
123 |
Issue: |
26 |
Pages: |
4077-88 |
|
•
•
•
•
•
|
Publication |
First Author: |
Le Gall SM |
Year: |
2010 |
Journal: |
J Cell Sci |
Title: |
ADAM17 is regulated by a rapid and reversible mechanism that controls access to its catalytic site. |
Volume: |
123 |
Issue: |
Pt 22 |
Pages: |
3913-22 |
|
•
•
•
•
•
|
Publication |
First Author: |
Franzke CW |
Year: |
2012 |
Journal: |
J Exp Med |
Title: |
Epidermal ADAM17 maintains the skin barrier by regulating EGFR ligand-dependent terminal keratinocyte differentiation. |
Volume: |
209 |
Issue: |
6 |
Pages: |
1105-19 |
|
•
•
•
•
•
|
Publication |
First Author: |
Weskamp G |
Year: |
2020 |
Journal: |
J Biol Chem |
Title: |
ADAM17 stabilizes its interacting partner inactive Rhomboid 2 (iRhom2) but not inactive Rhomboid 1 (iRhom1). |
Volume: |
295 |
Issue: |
13 |
Pages: |
4350-4358 |
|
•
•
•
•
•
|
Publication |
First Author: |
Li X |
Year: |
2017 |
Journal: |
J Cell Sci |
Title: |
Structural modeling defines transmembrane residues in ADAM17 that are crucial for Rhbdf2-ADAM17-dependent proteolysis. |
Volume: |
130 |
Issue: |
5 |
Pages: |
868-878 |
|
•
•
•
•
•
|
Publication |
First Author: |
Gravano DM |
Year: |
2010 |
Journal: |
PLoS One |
Title: |
ADAM17 deletion in thymic epithelial cells alters aire expression without affecting T cell developmental progression. |
Volume: |
5 |
Issue: |
10 |
Pages: |
e13528 |
|
•
•
•
•
•
|
Publication |
First Author: |
Sahin U |
Year: |
2004 |
Journal: |
J Cell Biol |
Title: |
Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands. |
Volume: |
164 |
Issue: |
5 |
Pages: |
769-79 |
|
•
•
•
•
•
|
Publication |
First Author: |
Ma X |
Year: |
2021 |
Journal: |
J Biol Chem |
Title: |
ADAM17 mediates ectodomain shedding of the soluble VLDL receptor fragment in the retinal epithelium. |
Volume: |
297 |
Issue: |
4 |
Pages: |
101185 |
|
•
•
•
•
•
|
Publication |
First Author: |
Driscoll WS |
Year: |
2013 |
Journal: |
Circ Res |
Title: |
Macrophage ADAM17 deficiency augments CD36-dependent apoptotic cell uptake and the linked anti-inflammatory phenotype. |
Volume: |
113 |
Issue: |
1 |
Pages: |
52-61 |
|
•
•
•
•
•
|
Publication |
First Author: |
Takayanagi T |
Year: |
2016 |
Journal: |
Hypertension |
Title: |
Vascular ADAM17 as a Novel Therapeutic Target in Mediating Cardiovascular Hypertrophy and Perivascular Fibrosis Induced by Angiotensin II. |
Volume: |
68 |
Issue: |
4 |
Pages: |
949-955 |
|
•
•
•
•
•
|
Publication |
First Author: |
Li Q |
Year: |
2013 |
Journal: |
PLoS One |
Title: |
ADAM17 is critical for multipolar exit and radial migration of neuronal intermediate progenitor cells in mice cerebral cortex. |
Volume: |
8 |
Issue: |
6 |
Pages: |
e65703 |
|
•
•
•
•
•
|
Publication |
First Author: |
Lora J |
Year: |
2021 |
Journal: |
J Biol Chem |
Title: |
Targeted truncation of the ADAM17 cytoplasmic domain in mice results in protein destabilization and a hypomorphic phenotype. |
|
|
Pages: |
100733 |
|
•
•
•
•
•
|
Publication |
First Author: |
Fleck D |
Year: |
2013 |
Journal: |
J Neurosci |
Title: |
Dual cleavage of neuregulin 1 type III by BACE1 and ADAM17 liberates its EGF-like domain and allows paracrine signaling. |
Volume: |
33 |
Issue: |
18 |
Pages: |
7856-69 |
|
•
•
•
•
•
|
Publication |
First Author: |
Li N |
Year: |
2007 |
Journal: |
J Immunol |
Title: |
Non-cell autonomous expression of TNF-alpha-converting enzyme ADAM17 is required for normal lymphocyte development. |
Volume: |
178 |
Issue: |
7 |
Pages: |
4214-21 |
|
•
•
•
•
•
|
Publication |
First Author: |
Kawasaki K |
Year: |
2014 |
Journal: |
Proc Natl Acad Sci U S A |
Title: |
Genetic variants of Adam17 differentially regulate TGFβ signaling to modify vascular pathology in mice and humans. |
Volume: |
111 |
Issue: |
21 |
Pages: |
7723-8 |
|
•
•
•
•
•
|
Publication |
First Author: |
Tang J |
Year: |
2018 |
Journal: |
Mol Cell Biol |
Title: |
Neutrophil and macrophage cell surface CSF-1 shed by ADAM17 drives mouse macrophage proliferation in acute and chronic inflammation. |
|
|
|
|
•
•
•
•
•
|
Publication |
First Author: |
Mishra HK |
Year: |
2016 |
Journal: |
J Leukoc Biol |
Title: |
Targeting ADAM17 in leukocytes increases neutrophil recruitment and reduces bacterial spread during polymicrobial sepsis. |
Volume: |
100 |
Issue: |
5 |
Pages: |
999-1004 |
|
•
•
•
•
•
|
Publication |
First Author: |
Wilson CL |
Year: |
2013 |
Journal: |
Mech Dev |
Title: |
Endothelial deletion of ADAM17 in mice results in defective remodeling of the semilunar valves and cardiac dysfunction in adults. |
Volume: |
130 |
Issue: |
4-5 |
Pages: |
272-89 |
|
•
•
•
•
•
|
Publication |
First Author: |
Rabinowitsch AI |
Year: |
2023 |
Journal: |
J Cell Sci |
Title: |
Analysis of the function of ADAM17 in iRhom2 curly-bare and tylosis with esophageal cancer mutant mice. |
Volume: |
136 |
Issue: |
13 |
|
|
•
•
•
•
•
|
Publication |
First Author: |
Beck Gooz M |
Year: |
2014 |
Journal: |
Am J Physiol Renal Physiol |
Title: |
ADAM17 promotes proliferation of collecting duct kidney epithelial cells through ERK activation and increased glycolysis in polycystic kidney disease. |
Volume: |
307 |
Issue: |
5 |
Pages: |
F551-9 |
|
•
•
•
•
•
|
Publication |
First Author: |
Kawaguchi N |
Year: |
2007 |
Journal: |
J Cell Sci |
Title: |
Different ADAMs have distinct influences on Kit ligand processing: phorbol-ester-stimulated ectodomain shedding of Kitl1 by ADAM17 is reduced by ADAM19. |
Volume: |
120 |
Issue: |
Pt 6 |
Pages: |
943-52 |
|
•
•
•
•
•
|
Publication |
First Author: |
Yan I |
Year: |
2016 |
Journal: |
J Leukoc Biol |
Title: |
ADAM17 controls IL-6 signaling by cleavage of the murine IL-6Rα from the cell surface of leukocytes during inflammatory responses. |
Volume: |
99 |
Issue: |
5 |
Pages: |
749-60 |
|
•
•
•
•
•
|
Publication |
First Author: |
Folgosa L |
Year: |
2013 |
Journal: |
J Immunol |
Title: |
Disturbed follicular architecture in B cell A disintegrin and metalloproteinase (ADAM)10 knockouts is mediated by compensatory increases in ADAM17 and TNF-α shedding. |
Volume: |
191 |
Issue: |
12 |
Pages: |
5951-8 |
|
•
•
•
•
•
|
Publication |
First Author: |
DeBerge MP |
Year: |
2015 |
Journal: |
J Leukoc Biol |
Title: |
Shedding of TNF receptor 2 by effector CD8⁺ T cells by ADAM17 is important for regulating TNF-α availability during influenza infection. |
Volume: |
98 |
Issue: |
3 |
Pages: |
423-34 |
|
•
•
•
•
•
|
Protein |
Organism: |
Mus musculus/domesticus |
Length: |
827
 |
Fragment?: |
false |
|
•
•
•
•
•
|
Protein |
Organism: |
Mus musculus/domesticus |
Length: |
827
 |
Fragment?: |
false |
|
•
•
•
•
•
|
Publication |
First Author: |
Lorenzen I |
Year: |
2011 |
Journal: |
Biochem Biophys Res Commun |
Title: |
Multimerisation of A disintegrin and metalloprotease protein-17 (ADAM17) is mediated by its EGF-like domain. |
Volume: |
415 |
Issue: |
2 |
Pages: |
330-6 |
|
•
•
•
•
•
|
Publication |
First Author: |
Maretzky T |
Year: |
2011 |
Journal: |
Nat Commun |
Title: |
Migration of growth factor-stimulated epithelial and endothelial cells depends on EGFR transactivation by ADAM17. |
Volume: |
2 |
|
Pages: |
229 |
|
•
•
•
•
•
|
Publication |
First Author: |
Veit M |
Year: |
2019 |
Journal: |
Life Sci Alliance |
Title: |
Mutagenesis of the ADAM17-phosphatidylserine-binding motif leads to embryonic lethality in mice. |
Volume: |
2 |
Issue: |
5 |
|
|
•
•
•
•
•
|